Literature DB >> 10866907

Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery.

H M Yeh1, L K Chen, C J Lin, W H Chan, Y P Chen, C S Lin, W Z Sun, M J Wang, S K Tsai.   

Abstract

UNLABELLED: Pruritus is a common side effect of intrathecal morphine injection for postoperative pain control. Its incidence is especially high in patients undergoing cesarean delivery. We investigated the effectiveness of ondansetron in preventing intrathecal morphine-induced pruritus in such patients. We included 60 consecutive nonbreastfeeding women who were scheduled for elective cesarean delivery. After the administration of spinal anesthesia with bupivacaine and intrathecal morphine 0.15 mg injection, the patients were randomly divided into three groups. Group 1 received placebo (normal saline) IV injection, Group 2 diphenhydramine 30 mg IV injection, and Group 3 ondansetron 0.1 mg/kg IV injection. The incidence of pruritus was significantly lower in the ondansetron group (25%) when compared with that in the placebo group (85%) and in the diphenhydramine group (80%) (both P < 0.05). The postoperative pain score and time to flatus passage were not significantly different among the three groups. There were no headache or extrapyramidal signs associated with ondansetron use. In conclusion, ondansetron prophylaxis significantly reduced the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. IMPLICATIONS: Ondansetron prophylaxis significantly decreases the incidence of pruritus, a common side effect of intrathecal morphine used to treat postcesarean delivery pain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10866907     DOI: 10.1097/00000539-200007000-00032

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  23 in total

Review 1.  Intrathecal opioids for combined spinal-epidural analgesia during labour.

Authors:  Peter DeBalli; Terrance W Breen
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Effects of fentanyl added to a mixture of intrathecal bupivacaine and morphine for spinal anaesthesia in elective caesearean section.

Authors:  Patrick Thornton; Deepak Hanumanthaiah; Ruth Aoibheann O'Leary; Gabriella Iohom
Journal:  Rom J Anaesth Intensive Care       Date:  2015-10

4.  Ondansetron treatment in a child presenting with chronic intractable pruritus.

Authors:  Chantal Frigon; Joëlle Desparmet
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

5.  Intrathecal morphine for postoperative pain control following robot-assisted prostatectomy: a prospective randomized trial.

Authors:  Junyeol Bae; Hyun-Chang Kim; Deok Man Hong
Journal:  J Anesth       Date:  2017-05-05       Impact factor: 2.078

Review 6.  Neuraxial opioid-induced itch and its pharmacological antagonism.

Authors:  Mei-Chuan Ko
Journal:  Handb Exp Pharmacol       Date:  2015

Review 7.  Pathophysiology and management of opioid-induced pruritus.

Authors:  Arjunan Ganesh; Lynne G Maxwell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Lornoxicam and ondansetron for the prevention of intrathecal fentanyl-induced pruritus.

Authors:  Nurcin Gulhas; Feray Akgul Erdil; Ozlem Sagir; Ender Gedik; Turkan Togal; Zekine Begec; M Ozcan Ersoy
Journal:  J Anesth       Date:  2007-05-30       Impact factor: 2.078

9.  Compatibility and stability of morphine sulphate and naloxone hydrochloride in 0.9% sodium chloride for injection.

Authors:  Charlotte Kistner; Mary H H Ensom; Diane Decarie; Gillian Lauder; Roxane R Carr
Journal:  Can J Hosp Pharm       Date:  2013-05

Review 10.  Side Effects and Efficacy of Neuraxial Opioids in Pregnant Patients at Delivery: A Comprehensive Review.

Authors:  Sarah Armstrong; Roshan Fernando
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.